A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
← catalyst calendarSponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Ireland Limited.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
86estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-03 | actual | When the study began enrolling |
| Primary completion | 2026-07-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: JZP047
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Reporting Treatment-emergent Adverse Events (Part A)
measured Baseline up to Day 90
Number of Participants Reporting Treatment-emergent Adverse Events (Part B)
measured Baseline up to Day 90
Number of Participants Who Discontinued The Study (Part A)
measured Baseline up to Day 90
Number of Participants Who Discontinued The Study (Part B)
measured Baseline up to Day 90
Pharmacokinetic Parameter Maximum Concentration (Part A)
measured Up to 90 days
Pharmacokinetic Parameter Time to Maximum Concentration and Time Before the Start of Absorption (Part A)
measured Up to 90 days
Pharmacokinetic Parameter Terminal Elimination Half-life (Part A)
measured Up to 90 days
Pharmacokinetic Parameter Terminal Elimination Rate Constant (Part A)
measured Up to 90 days
Pharmacokinetic Parameter Volume of Distribution During Terminal Phase (Part A)
measured Up to 90 days
Pharmacokinetic Parameter Oral Clearance (Part A)
measured Up to 90 days
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (Part A)
measured Up to 90 days
Pharmacokinetic Parameter Percentage of The Area Under the Concentration-Time Curve From Time Infinity Due to Extrapolation From The Last Quantifiable Concentration to Time Infinity (Part A)
measured Up to 90 days
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed